Terms: = Head and neck cancer AND uPA AND Prognosis
41 results:
1. Transforming growth factor-β signals promote progression of squamous cell carcinoma by inducing epithelial-mesenchymal transition and angiogenesis.
Ibi H; Takahashi K; Harada H; Watabe T; Podyma-Inoue KA
Biochem Biophys Res Commun; 2024 Jun; 714():149965. PubMed ID: 38657447
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic evaluation of oral squamous cell carcinoma based on pleiotrophin, urokinase plasminogen activator, and glycoprotein nonmetastatic melanoma protein B expression.
Ma Y; Liu Y; Meng H
Medicine (Baltimore); 2023 Nov; 102(45):e35634. PubMed ID: 37960806
[TBL] [Abstract] [Full Text] [Related]
3. In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid cancer Cell Lines.
Baldini E; Presutti D; Favoriti P; Santini S; Papoff G; Tuccilli C; Carletti R; Di Gioia C; Lori E; Ferent IC; Gagliardi F; Catania A; Pironi D; Tripodi D; D'Andrea V; Sorrenti S; Ruberti G; Ulisse S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409084
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA-378-3p/5p suppresses the migration and invasiveness of oral squamous carcinoma cells by inhibiting KLK4 expression.
Cui Z; Sun S; Liu Q; Zhou X; Gao S; Peng P; Li Q
Biochem Cell Biol; 2020 Apr; 98(2):154-163. PubMed ID: 31265790
[TBL] [Abstract] [Full Text] [Related]
5. Circulating upa as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma.
He X; Xu X; Zhu G; Ye H
Medicine (Baltimore); 2019 Mar; 98(9):e14717. PubMed ID: 30817615
[TBL] [Abstract] [Full Text] [Related]
6. XBP1 promotes tumor invasion and is associated with poor prognosis in oral squamous cell carcinoma.
Sun Y; Jiang F; Pan Y; Chen X; Chen J; Wang Y; Zheng X; Zhang J
Oncol Rep; 2018 Aug; 40(2):988-998. PubMed ID: 29916547
[TBL] [Abstract] [Full Text] [Related]
7. TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling.
Zhang B; Zhang Z; Li L; Qin YR; Liu H; Jiang C; Zeng TT; Li MQ; Xie D; Li Y; Guan XY; Zhu YH
Nat Commun; 2018 Apr; 9(1):1423. PubMed ID: 29650964
[TBL] [Abstract] [Full Text] [Related]
8. Diallyl disulfide inhibits the metastasis of type Ⅱ esophageal‑gastric junction adenocarcinoma cells via NF-κB and PI3K/AKT signaling pathways in vitro.
Yin X; Feng C; Han L; Ma Y; Jiao Y; Wang J; Jia L; Jing F; Gao X; Zhang Y; Zhang J
Oncol Rep; 2018 Feb; 39(2):784-794. PubMed ID: 29207122
[TBL] [Abstract] [Full Text] [Related]
9. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract] [Full Text] [Related]
10. Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Tian B; Chen X; Zhang H; Li X; Wang J; Han W; Zhang LY; Fu L; Li Y; Nie C; Zhao Y; Tan X; Wang H; Guan XY; Hong A
Oncotarget; 2017 Jun; 8(26):42300-42313. PubMed ID: 28404945
[TBL] [Abstract] [Full Text] [Related]
11. upa/upaR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract] [Full Text] [Related]
12. Alpha B-crystallin - a validated prognostic factor for poor prognosis in squamous cell carcinoma of the oral cavity.
Annertz K; Enoksson J; Williams R; Jacobsson H; Coman WB; Wennerberg J
Acta Otolaryngol; 2014 May; 134(5):543-50. PubMed ID: 24702231
[TBL] [Abstract] [Full Text] [Related]
13. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract] [Full Text] [Related]
14. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract] [Full Text] [Related]
15. Relationships of upa and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis.
Jiang JT; Zhang LF; Zhou B; Zhang SQ; Li SM; Zhang W; Zhang J; Qiao Z; Kong RR; Ma YF; Chen S
Asian Pac J Cancer Prev; 2012; 13(7):3379-83. PubMed ID: 22994764
[TBL] [Abstract] [Full Text] [Related]
16. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract] [Full Text] [Related]
17. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract] [Full Text] [Related]
18. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual upa and MMP-activated engineered anthrax toxin.
Schafer JM; Peters DE; Morley T; Liu S; Molinolo AA; Leppla SH; Bugge TH
PLoS One; 2011; 6(5):e20532. PubMed ID: 21655226
[TBL] [Abstract] [Full Text] [Related]
19. Impact of upa system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
Weng CJ; Lin CW; Chung TT; Tsai CM; Chen MK; Yang SF
Ann Surg Oncol; 2011 Mar; 18(3):805-12. PubMed ID: 21125336
[TBL] [Abstract] [Full Text] [Related]
20. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract] [Full Text] [Related]
[Next]
